Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

PRAGUE & AMSTERDAM, March 13, 2025--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its ...

Prague headquartered clinical-stage firm SOTIO Biotech, which is owned by the Czech Republic's PPF Group, today announced it ...

Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology ...

Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform technology for designing and ...

Synaffix, a rapidly growing Dutch biotechnology company, offers a clinical-stage antibody–drug conjugate (ADC) and targeted delivery platform with broad relevance across the therapeutic spectrum.

Lonza acquired Synaffix, a biotechnology company focused on commercializing its clinical-stage technology platform for the development of more effective and better tolerated antibody-drug conjugates ...

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day. Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a ...

The bispecific antibody candidates were identified by SOTIO’s research team and will now be developed under SOTIO’s license and option agreement with Synaffix, which enables SOTIO to combine ...

PRAGUE & AMSTERDAM–(BUSINESS WIRE)–SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option ...